Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lyon Cedez 07, France Clinical Trials

A listing of Lyon Cedez 07, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

Treatment of non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation is mainly based on tyrosine kinase inhibitors (TKIs) targeting EGFR. 1st or 2nd generation inhibitors have been shown to be superior to chemotherapy in terms of Progression-Free Survival (PFS) when used as 1st line treatment. In …

Phase

0.0 miles

Learn More »

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

First stage : Arm A: Nivolumab + Cyclophosphamide-Vinblastine Arm B: Nivolumab + Capecitabin Arm C: Nivolumab + Cyclophosphamide-Vinblastine + Capecitabin Arm A and Arm B will be initially allocated sequentially (A/B/A/B/A/B). Arm C will be opened, if arm A and Arm B are deemed safe. In each arm, the second …

Phase

0.0 miles

Learn More »

Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?

To perform this, all patient undergoing oncological fertility preservation will be evaluated for COVID-19 symptomatology (fever, cough, headache, myalgia, diarrhea, anosmia, pharyngodynia). In addition, a nasopharyngeal swab for SARS-CoV-2 research by RT- qPCR will be performed on the day of semen collection. On the same day, serological tests will be …

Phase N/A

0.1 miles

Learn More »

Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

This multicenter, prospective, open-labeled 2-arm, randomized non-comparative phase II trial. This phase II trial is based on a 2-stage Simon's optimal design. Randomization 1:1 with 1 patient randomized in experimental arm A (association of nivolumab plus relatlimab) and 1 patient randomized in arm B (treatment by nivolumab alone).

Phase

0.1 miles

Learn More »

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

Carcinosarcomas (CS) (malignant mixed Mllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies …

Phase

0.62 miles

Learn More »

Cultured Autologous Oral Mucosa Epithelial Sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency

Some severe ocular burns or other rare ocular pathologies can be associated with a total loss of corneal epithelial stem cells (i.e. Limbal Stem Cell Deficiency - LSCD), which leads to cornea invasion by the conjunctiva and a subsequent opacification. When LSCD is total and bilateral, both eyes are affected …

Phase

1.03 miles

Learn More »

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma or Malignant Pheochromocytoma/Paraganglioma

EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered in combination with nivolumab to generate preliminary safety and efficacy data in patients with Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma.

Phase

2.78 miles

Learn More »

Emotion Assessment to Study Consciousness in Awakening Patients

After a coma, one important challenge is the detection of awareness with patients with disorders of consciousness. For some patients, the only behavioral manifestation indicative of awareness is an appropriate emotional response. Studies show that the use of a particular conditioning - with delay - appears to be an objective …

Phase N/A

4.32 miles

Learn More »

Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.

In 2014, the International Myeloma Working Group (IMWG) proposed a revised classification of multiple myeloma (MM) and smoldering myeloma (SMM). Since the new definition of SMM proposed excludes "ultra-high risk SMM", the evolution profile of SMM will change. Therefore, investigators need to update their knowledge of SMM to optimize the …

Phase N/A

7.01 miles

Learn More »